The status of pharmacotherapy for autism spectrum disorders

@article{Myers2007TheSO,
  title={The status of pharmacotherapy for autism spectrum disorders},
  author={Scott M. Myers},
  journal={Expert Opinion on Pharmacotherapy},
  year={2007},
  volume={8},
  pages={1579 - 1603}
}
  • S. Myers
  • Published 1 August 2007
  • Medicine
  • Expert Opinion on Pharmacotherapy
The use of pharmacologic agents as a component of treatment for children and adults with autism spectrum disorders is common and a substantial body of literature describing controlled and open-label clinical trials now exists to guide clinical practice. Empiric evidence of efficacy of risperidone, methylphenidate and some selective serotonin re-uptake inhibitors for maladaptive behaviors commonly associated with autism spectrum disorders has increased substantially in recent years. Preliminary… Expand
Psychotropic drug efficacy and side effects for persons with autism spectrum disorders
TLDR
Assessment of current prescription practices to determine what is needed with respect to better understanding the cost and benefits of these prescription practices, and notions about future trends in research to better aid in the understanding of psychotropic drug side effects. Expand
Atomoxetine for Treating ADHD Symptoms in Autism
  • A. Ghanizadeh
  • Psychology, Medicine
  • Journal of attention disorders
  • 2013
TLDR
There are not enough controlled clinical trials for showing the efficacy of atomoxetine for treatment of ADHD symptoms in autism and there is no evidence that it is effective in high-functioning patients with autism or patients with low severity. Expand
Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment
The Diagnostic and Statistical Manual of Mental Disorders (4th Edition) prohibits the co-diagnosis of attention-deficit/hyperactivity disorder (ADHD) and an autism spectrum disorder (ASD). However,Expand
Polypharmacy profiles and predictors among adults with autism spectrum disorders
TLDR
Medication profiles and predictors of polypharmacy among 142 adults with ASD who had experienced a psychiatric crisis, including history of aggression, residence, and psychiatric support were examined. Expand
Pharmacological management of core and comorbid symptoms in autism-spectrum disorder
In this article we review the evidence base and practical experience supporting the use of psycho-pharmacological treatments for autism-spectrum disorders across the lifespan. Recent advances inExpand
Management of Symptoms in Children With Autism Spectrum Disorders: A Comprehensive Review of Pharmacologic and Complementary-Alternative Medicine Treatments
TLDR
A review of 115 studies adds to the ASD treatment literature by aggregating studies of pharmacologic treatments and CAM treatments and organizing treatment response by ASD symptoms, differentiating core and associated symptoms. Expand
Efficacy of Atomoxetine for the Treatment of ADHD Symptoms in Patients With Pervasive Developmental Disorders
TLDR
Atomoxetine appears to be a useful drug, pointing to the need for larger, randomized, controlled, double-blind studies to confirm its efficacy versus placebo and in comparison with other treatment options. Expand
Management of Children With Autism Spectrum Disorders
TLDR
Important issues, such as management of associated medical problems, pharmacologic and nonpharmacologic intervention for challenging behaviors or coexisting mental health conditions, and use of complementary and alternative medical treatments, are also addressed. Expand
Treating pediatric patients with antipsychotic drugs: balancing benefits and safety.
TLDR
This article reviews the current trends for the therapeutic use of antipsychotic medications in pediatric psychiatry and the available data that support their efficacy, but it also discusses important issues related to their safety during both short-term and long-term administration. Expand
Atypical and Typical Antipsychotics in the Schools.
The use of antipsychotic medications within the school-age population is rapidly increasing. Although typical antipsychotics may be used in rare cases, this influx is largely secondary to theExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 335 REFERENCES
Safety issues with drug therapies for autism spectrum disorders.
Although currently no medication has been approved to treat autism spectrum disorders, survey data show that community practitioners are prescribing a broad range of medication treatments, including,Expand
Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.
TLDR
Although SSRIs may demonstrate therapeutic benefit in autism spectrum disorders, methodological weaknesses of many of the clinical trials suggest the need for additional randomized controlled trials. Expand
The use of selective serotonin reuptake inhibitors in autism and related disorders.
TLDR
This paper reviews the published literature on the use of selective serotonin reuptake inhibitors for the treatment of symptoms associated with autistic disorder and other pervasive developmental disorders (PDDs) in both children and adults and concludes that larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment. Expand
Novel treatments for autistic spectrum disorders.
  • S. Levy, S. Hyman
  • Medicine
  • Mental retardation and developmental disabilities research reviews
  • 2005
TLDR
Secretin as a therapy for autism is discussed as an example of how a clinical observation rapidly grew to a widespread treatment before well-designed studies demonstrated absence of effect. Expand
Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report
TLDR
Control treatment trials with venlafaxine are warranted in autism spectrum disorders after improvement was noted in repetitive behaviors and restricted interests, social deficits, communication and language function, inattention, and hyperactivity. Expand
Risperidone in children with autism and serious behavioral problems.
TLDR
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months. Expand
Targeted treatments for symptom domains in child and adolescent autism
TLDR
These and other studies show how developments in study design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Expand
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.
  • M. Aman
  • Psychology, Medicine
  • Seminars in pediatric neurology
  • 2004
TLDR
More research is needed on the management of all of these target symptoms, both for new agents (e.g., atomoxetine) and for established psychoactive medicines. Expand
Antiepileptic drugs: affective use in autism spectrum disorders.
TLDR
There is evidence that autism, epilepsy, and affective disorders commonly co-occur, and that they may share a common neurochemical substrate, which is the common target of the psychotropic mechanism of action of different antiepileptic drugs. Expand
Treating Functional Impairment of Autism with Selective Serotonin-Reuptake Inhibitors
TLDR
Benefits with SSRIs in treating functional impairments in autism have been observed and current evidence does not support selection of one SSRI over another for any impairment associated with autism. Expand
...
1
2
3
4
5
...